Capecitabine

Revision as of 19:31, 27 September 2011 by WikiBot (talk | contribs) (Protected "Capecitabine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Capecitabine
Clinical data
Pregnancy
category
  • AU: D
  • US: D (Evidence of risk)
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
Pharmacokinetic data
BioavailabilityExtensive
Protein binding< 60%
MetabolismHepatic, to 5'-DFCR, 5'-DFUR (inactive); neoplastic tissue, 5'-DFUR to active fluorouracil
Elimination half-life38–45 minutes
ExcretionRenal 95.5%, faecal 2.6%
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC15H22FN3O6
Molar mass359.35 g/mol

WikiDoc Resources for Capecitabine

Articles

Most recent articles on Capecitabine

Most cited articles on Capecitabine

Review articles on Capecitabine

Articles on Capecitabine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Capecitabine

Images of Capecitabine

Photos of Capecitabine

Podcasts & MP3s on Capecitabine

Videos on Capecitabine

Evidence Based Medicine

Cochrane Collaboration on Capecitabine

Bandolier on Capecitabine

TRIP on Capecitabine

Clinical Trials

Ongoing Trials on Capecitabine at Clinical Trials.gov

Trial results on Capecitabine

Clinical Trials on Capecitabine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Capecitabine

NICE Guidance on Capecitabine

NHS PRODIGY Guidance

FDA on Capecitabine

CDC on Capecitabine

Books

Books on Capecitabine

News

Capecitabine in the news

Be alerted to news on Capecitabine

News trends on Capecitabine

Commentary

Blogs on Capecitabine

Definitions

Definitions of Capecitabine

Patient Resources / Community

Patient resources on Capecitabine

Discussion groups on Capecitabine

Patient Handouts on Capecitabine

Directions to Hospitals Treating Capecitabine

Risk calculators and risk factors for Capecitabine

Healthcare Provider Resources

Symptoms of Capecitabine

Causes & Risk Factors for Capecitabine

Diagnostic studies for Capecitabine

Treatment of Capecitabine

Continuing Medical Education (CME)

CME Programs on Capecitabine

International

Capecitabine en Espanol

Capecitabine en Francais

Business

Capecitabine in the Marketplace

Patents on Capecitabine

Experimental / Informatics

List of terms related to Capecitabine

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Capecitabine (INN) (IPA: Template:IPA) is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. The activation of capecitabine follows a pathway with three enzymatic steps and two intermediary metabolites, 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouridine (5'-DFUR), to form 5-fluorouracil. Capecitabine is marketed under the trade name Xeloda (Roche).

Indications

Capecitabine is FDA-approved for:

  • Adjuvant in colorectal cancer Stage III Dukes' C - used as first-line monotherapy.
  • Metastatic colorectal cancer - used as first-line monotherapy, if appropriate.
  • Metastatic breast cancer - used in combination with docetaxel, after failure of anthracycline-based treatment. Also as monotherapy, if the patient has failed paclitaxel-based treatment, and if anthracycline-based treatment has either failed or cannot be continued for other reasons (i.e., the patient has already received the maximum lifetime dose of an anthracycline).

In the UK, capecitabine is approved by the National Institute for Health and Clinical Excellence (NICE) for colon and colorectal cancer, and locally advanced or metastatic breast cancer[2].

Dose

The usual starting dose is 2,500 mg/m2/day in two divided doses, 12 hours apart. One cycle includes two weeks of treatment followed by one week without treatment. Cycles can be repeated every three weeks.

Dose adjustments

  • For mild renal dysfunction (creatinine clearance 30-50 mL/min), it is recommended to reduce dose by 25%.
  • For severe renal dysfunction (creatinine clearance <30 mL/min), treatment is not recommended.
  • There is no recommendation for hepatic dysfunction.
  • For elderly patients, lower doses may be required due to higher incidences of serious adverse reactions.

Side effects

Potential major adverse reactions include:

Drug interactions

  • May interact with warfarin and increase bleeding risk.
  • May inhibit cytochrome CYP2C9 enzyme, and therefore increase levels of substrates such as phenytoin and other substrates of CYP2C9.
  • Much as fluorouracil, the concomitant use of leucovorin may increase both the efficacy and the toxicity of capecitabine.
Xeloda Logo

Formulation

Capecitabine (as brand-name Xeloda®) is available in light peach 150 mg tablets and peach 500 mg tablets.

References

  • Lacy, Charles F; Armstrong, Lora L; Goldman, Morton P; Lance, Leonard L (2004). Lexi-Comp's Drug Information Handbook (12th Edition). Lexi-Comp Inc. ISBN 1-59195-083-X
  • Fischer, David S; Knobf, M Tish; Durivage, Henry J; Beaulieu, Nancy J (2003). The Cancer Chemotherapy Handbook (6th Edition). Mosby. ISBN 0-323-01890-4
  • Thomson Centerwatch: Drugs Approved by the FDA (Xeloda) Retrieved 6/05

External links

  • Xeloda.com(patient information, tools, and resources)
  • [3] (patient information)

Template:SIB

de:Capecitabin

Template:WikiDoc Sources